Newsroom

News

The COVID-19 pandemic has dramatically demonstrated that the development of effective agents against viral pathogens is of great importance for global health. Although effective vaccines are available for many viral diseases, there is an urgent need for new and effective therapeutic treatments. At the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), the team led by Prof Rolf Müller is researching novel active substances for the treatment of infections. In their latest studies, the researchers were able to identify two new natural product families with promising activity against viruses. Their results have now been published in the journal Angewandte Chemie International Edition.

20.03.2023

HZI Campus

TWINCORE

HIPS

News

Infection with SARS-CoV-2 leads to severe disease in some people, whereas others do not get ill or only experience mild disease. What causes these differences is not fully understood. It is already known that an overactive innate immune system is causing severe COVID-19 disease, but it is unclear how this is regulated. A team led by Prof Yang Li, Director at the Centre for Individualised Infection Medicine (CiiM) and head of department “Computational Biology for Individualised Medicine” at the Helmholtz Centre for Infection Research (HZI), has come a step closer to answering this question. The researchers addressed the question to what extent the course of disease is genetically or epigenetically regulated. The CiiM is a joint initiative by the HZI and Hannover Medical School (MHH). In addition to Li, the team included other scientists from the HZI and the RESIST cluster of excellence.

23.02.2023

HZI Campus

CiiM

HIRI

News

22.02.2023

HZI Campus

TWINCORE

CRC

Fluorescence microscopic image of a zebrafish larva in which neutrophil granulocytes

News

In the ImageTox project, the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and the CISPA Helmholtz Center for Information Security are pooling their expertise in the fields of drug discovery and artificial intelligence (AI). Using state-of-the-art machine learning methods, the two Saarbrücken institutes aim to make research into the modes of action of new drugs more efficient. The project is an initiative within the Helmholtz Medical Security, Privacy, and AI Research Center (HMSP), which brings together leading experts from the fields of IT security, data privacy and AI, and medicine to solve pressing medical challenges. ImageTox is funded with 200,000 euros from Helmholtz Imaging, an initiative to promote imaging research.

15.02.2023

HIPS

News

Systematically attenuating DNA targeting activity can achieve CRISPR-driven editing in bacteria, greatly boosting colony counts and even increasing the frequency of precise genome editing. This was shown in a study of the Helmholtz Institute Würzburg (HIRI) in collaboration with the Helmholtz Centre for Infection Research (HZI) in Braunschweig. The findings were published today in the journal Nature Communications.

09.02.2023

HZI Campus

HIRI

News

Before new drugs can be tested in animal experiments and later in clinical trials, they must undergo a large number of laboratory tests. This involves the use of so-called cell lines, i.e. human or animal cells of a specific tissue that can be cultivated in the laboratory. A team led by Prof Claus-Michael Lehr of the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) has now developed a novel human lung cell line that should enable much more accurate predictions of the behavior of active substances or dosage forms in humans than previous systems. The cell line could be used, among other things, in the development of drugs against SARS-CoV-2. The scientists published their results in the journal Advanced Science.

08.02.2023

HIPS

Back to the first page
...
34
35
36
37
...
147

HZI in the media

... diesem Ergebnis kommt ein Forschungsteam des Helmholtz-Zentrums für Infektionsforschung (HZI) in Zusammenarbeit mit der ...

14.10.2025

Deutsches Ärzteblatt

Individualisierte Infektionsmedizin, einer gemeinsamen Einrichtung des Helmholtz-Zentrums für Infektionsforschung und der MHH. Bis zuletzt

13.10.2025

Springer

Ein Grippe-Test könnte in Zukunft womöglich sehr schnell gehen: einfach ein Kaugummi kauen. Ein deutsches ...

09.10.2025

Apotheken Umschau

... am 1. Oktober 2025. Das HIPS ist ein Standort des Helmholtz-Zentrums für Infektionsforschung (HZI) in ...

07.10.2025

juraforum.de

... „Epidemiologie und Ökologie antimikrobieller Resistenz“ am HZI-Standort Helmholtz-Institut für One Health (HIOH), am Projekt ...

06.10.2025

Bochumer-Zeitung

” says Mark Brönstrup, a professor at both the Helmholtz Center for Infection Research and Leibniz University Hannover, who wasn’t involved

04.10.2025

MIT CSAIL

... Hannover (MHH) und Klinischer Direktor des Helmholtz-Zentrums für Infektionsforschung (HZI). Auch an der Gründung des ...

03.10.2025

Deutsches Ärzteblatt

... des Sensormoleküls

Prof. Carlos A. Guzmán (Helmholtz-Zentrum für Infektionsforschung, Braunschweig) mit den Teams um Dr. ...

02.10.2025

Medizin Aspekte

... ” Seit Mai 2025 im Humanprogramm des Helmholtz-Zentrums für Infektionsforschung (HZI), Dr. Max Kellner-Leiter der jungen ...

25.09.2025

Die heutigen Nachrichten

” (Vico) within the Human program at the Helmholtz Centre for Infection Research (HZI).the‌ Vico group continues to investigate resilience

25.09.2025

World Today News

Forschende des Helmholtz-Instituts für RNA-basierte Infektionsforschung (HIRI), einem Standort des Braunschweiger Helmholtz-Zentrums für ...

19.09.2025

Verband Deutscher Biologen e.V.

purposes.

Researchers at the HIRI, a site of the Braunschweig Helmholtz Center for Infection Research (HZI), in cooperation with the Julius

19.09.2025

NewsBreak

Register now for the HZI-Newsletter

and stay up to date!

Email address *

We use rapidmail to send our newsletter. I agree that my data entered here will be transmitted to rapidmail. I have taken note of the HZI's privacy policy and have been informed of my rights.